Improved Eradication Rate of Standard Triple Therapy by Adding Bismuth and Probiotic Supplement for Helicobacter pylori Treatment in Thailand |
Srinarong, Chanagune
(Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University Hospital)
Siramolpiwat, Sith (Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University Hospital) Wongcha-um, Arti (The University of Southampton) Mahachai, Varocha (Gastrointestinal and Liver Center, Bangkok Medical Center) Vilaichone, Ratha-Korn (Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University Hospital) |
1 | Abebaw W,Kibret M, Abera B (2014). Prevalence and risk factors of H. pylori from dyspeptic patients in northwest Ethiopia: a hospital based cross-sectional study. Asian Pac J Cancer Prev, 15, 4459-63. 과학기술학회마을 DOI ScienceOn |
2 | Armuzzi A, Cremonini F, Bartolozzi F, et al (2001). The effect of oral administration of Lactobacillus GG on antibioticassociated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther, 15, 163-9. DOI ScienceOn |
3 | Armuzzi A, Cremonini F, Ojetti V, et al (2001). Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion, 63, 1-7. |
4 | Basiri Z, Safaralizadeh R, Bonyadi MJ, et al (2014). Helicobacter pylori vacA d1 genotype predicts risk of gastric adenocarcinoma and peptic ulcers in northwestern Iran. Asian Pac J Cancer Prev, 15, 1575-9. 과학기술학회마을 DOI ScienceOn |
5 | Chey WD, Wong BC (2007). American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol, 102, 1808-25. DOI ScienceOn |
6 | de Martel C, Ferlay J, Franceschi S, et al (2012). Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol, 13, 607-15. DOI ScienceOn |
7 | Demirel BB, Akkas BE, Vural GU (2013). Clinical factors related with Helicobacter pylori infection--is there an association with gastric cancer history in first-degree family members? Asian Pac J Cancer Prev, 14, 1797-802. 과학기술학회마을 DOI ScienceOn |
8 | Du YQ, Su T, Fan JG, et al (2012). Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection. World J Gastroenterol, 18, 6302-7. DOI |
9 | Fock KM (2014). Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther, 40, 250-60. DOI |
10 | Fock KM, Katelaris P, Sugano K, et al (2009). Second Asia- Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol, 24, 1587-1600. DOI ScienceOn |
11 | Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P (2014). Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ, 348, 3174. DOI |
12 | Ford AC, Malfertheiner P, Giguere M, et al (2008). Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol, 14, 7361-70. DOI |
13 | Hajmanoochehri F, Mohammadi N, Nasirian N, Hosseinkhani M (2013). Patho-epidemiological features of esophageal and gastric cancers in an endemic region: a 20-year retrospective study. Asian Pac J Cancer Prev, 14, 3491-7. 과학기술학회마을 DOI ScienceOn |
14 | Fuller R (1991). Probiotics in human medicine. Gut, 32, 439-42. DOI ScienceOn |
15 | Graham DY (2009). Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol, 7, 145-8. DOI |
16 | Graham DY, Lu H, Yamaoka Y (2007). A report card to grade Helicobacter pylori therapy. Helicobacter, 12, 275-8. DOI ScienceOn |
17 | IARC (1994) Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum, 61, 1-241. |
18 | Karami N, Talebkhan Y, Saberi S, et al (2013). Seroreactivity to Helicobacter pylori antigens as a risk indicator of gastric cancer. Asian Pac J Cancer Prev, 14, 1813-7. 과학기술학회마을 DOI ScienceOn |
19 | Lin WL, Sun JL, Chang SC, et al (2014). Factors predicting survival of patients with gastric cancer. Asian Pac J Cancer Prev, 15, 5835-8. 과학기술학회마을 DOI ScienceOn |
20 | Mahachai V, Sirimontaporn N, Tumwasorn S, Thong-Ngam D, Vilaichone RK (2011). Sequential therapy in clarithromycinsensitive and -resistant Helicobacter pylori based on polymerase chain reaction molecular test. J Gastroenterol Hepatol, 26, 825-8. DOI |
21 | Parsonnet J, Friedman GD, Vandersteen DP, et al (1991). Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med, 325, 1127-31. DOI ScienceOn |
22 | Malfertheiner P, Megraud F, O'Morain CA, et al (2012). Management of helicobacter pylori infection--the maastricht iv/ florence consensus report. Gut, 61, 646-64. DOI ScienceOn |
23 | Mirzaee V, Rezahosseini O (2012). Randomized control trial: comparison of triple therapy plus probiotic yogurt vs. standard triple therapy on Helicobacter pylori Eradication. Iran Red Crescent Med J, 14, 657-66. |
24 | Otles S, Cagindi O, Akcicek E (2003). Probiotics and health. Asian Pac J Cancer Prev, 4, 369-72. |
25 | Prasertpetmanee S, Mahachai V, Vilaichone RK (2013). Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy. Helicobacter, 18, 270-3. DOI |
26 | Rahman R, Asombang AW, Ibdah JA (2014). Characteristics of gastric cancer in Asia. World J Gastroenterol, 20, 4483-90. DOI |
27 | Rimbara E, Fischbach LA, Graham DY (2011). Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol, 8, 79-88. DOI ScienceOn |
28 | Sheu BS, Cheng HC, Kao AW, et al (2006). Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am J Clin Nutr, 83, 864-9. |
29 | Uemura N, Okamoto S, Yamamoto S, et al (2001). Helicobacter pylori infection and the development of gastric cancer. N Engl J Med, 345, 784-9. DOI ScienceOn |
30 | Vilaichone RK, Mahachai V (2001). Current management of Helicobacter pylori infection. J Med Assoc Thai, 84, 32-38. |
31 | Vilaichone RK, Mahachai V, Graham DY (2006). Helicobacter pylori diagnosis and management. Gastroenterol Clin North Am, 35, 229-47. DOI ScienceOn |
32 | Wang YH, Huang Y (2014). Effect of Lactobacillus acidophilus and Bifidobacterium bifidum supplementation to standard triple therapy on Helicobacter pylori eradication and dynamic changes in intestinal flora. World J Microbiol Biotechnol, 30, 847-853. DOI |
33 | Zheng X, Lyu L, Mei Z (2013). Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig, 105, 445-53. DOI |